News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Vanda Pharmaceuticals, Inc. Sets IPO Price At $12-$14 Per Share
March 21, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
3/21/2006 – Vanda Pharmaceuticals Inc., which is developing small molecule product candidates for central nervous system disorders, said it has set the terms of its initial public offering of 5.75 million common shares at $12 to $14 per share.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
IPO tracker
Generate Clocks Largest IPO Since 2024 With $400M Raise
February 27, 2026
·
5 min read
·
Tristan Manalac
Deals
Boehringer Seeks To Rebalance Immunity With Sitryx Collab Potentially Worth $500M+
February 26, 2026
·
1 min read
·
Tristan Manalac
Gene editing
Pfizer Advances Beam’s Gene Editor After Pulling Hemophilia Gene Therapy
February 26, 2026
·
1 min read
·
Tristan Manalac
Weight loss
Novo Leans Into Oral Route With Weight Loss Partnership Worth up to $2.1B
February 25, 2026
·
2 min read
·
Tristan Manalac